• von Willebrand disease (VWD) is the most common inherited bleeding disorder.
Essentials
• von Willebrand disease (VWD) is the most common inherited bleeding disorder.
• Gene therapy for VWD offers long-term therapy for VWD patients.
• Transposons efficiently integrate the large von Willebrand factor (VWF) cDNA in mice.
• Liver-directed transposons support sustained VWF expression with suboptimal multimerization.
Summary. Background: Type 3 von Willebrand disease (VWD) is characterized by complete absence of von Willebrand factor (VWF). Current therapy is limited to treatment with exogenous VWF/FVIII products, which only provide a short-term solution. Gene therapy offers the potential for a long-term treatment for VWD. Objectives: To develop an integrative Sleeping Beauty (SB) transposon-mediated VWF gene transfer approach in a preclinical mouse model of severe VWD. Methods: We established a robust platform for sustained transgene murine VWF (mVWF) expression in the liver of Vwf À/À mice by combining a liver-specific promoter with a sandwich transposon design and the SB100X transposase via hydrodynamic gene delivery. Results: The sandwich SB transposon was suitable to deliver the full-length mVWF cDNA (8.4 kb) and supported supra-physiological expression that remained stable for up to 1.5 years after gene transfer. The sandwich vector stayed episomal (~60 weeks) or integrated in the host genome, respectively, in the absence or presence of the transposase. Transgene integration was confirmed using carbon tetrachloride-induced liver regeneration. Analysis of integration sites by high-throughput analysis revealed random integration of the sandwich vector. Although the SB vector supported long-term expression of supra-physiological VWF levels, the bleeding phenotype was not corrected in all mice. Long-term expression of VWF by hepatocytes resulted in relatively reduced amounts of high-molecularweight multimers, potentially limiting its hemostatic efficacy. Conclusions: Although this integrative platform for
Introduction
Recently, Sleeping Beauty (SB) transposon technology has become an attractive tool for integrative gene therapy in vertebrate cells, providing a promising alternative to viral vectors [1] . The two-component SB vector consists of the hyperactive SB transposase (SB100X) and the gene of interest flanked by inverted repeats (Fig. 1A ) [2] . SB transposition into a TA dinucleotide occurs through a conservative cut-and-paste mechanism [3] . The SB100X technology has already shown considerable potential for preclinical treatment of various genetic diseases and clinical trials were started for treatment of tumors and retinal degeneration [4, 5] . Although SB is not bound to absolute size-restrictions as seen with most viral vectors, an inverse correlation exists between transposition efficiency and transposon length [6, 7] . The sandwich-designed SB transposon, however, has an adapted SB configuration in which the DNA to be mobilized is flanked by two complete, but empty, SB elements arranged in an inverted orientation. Previous studies have shown that this sandwich design has superior ability to transpose > 10 kb transgenes and might be an attractive alternative for gene therapy of complex large transgenes [8, 9] .
von Willebrand factor (VWF) is a large gene, comprising 52 exons and 8.4 kb cDNA [10] . VWF is a large plasma glycoprotein produced by endothelial cells and megakaryocytes and circulates in plasma as multimers with a molecular weight of up to 20 000 kDa. VWF plays a crucial role in hemostasis by mediating platelet adhesion at sites of vascular injury and by stabilizing coagulation factor VIII (FVIII) [11, 12] . Mutations in the VWF gene can cause quantitative and/or qualitative abnormalities in the VWF protein, resulting in von Willebrand disease (VWD), the most common inherited bleeding Using a cut-and-paste mechanism the transposase (grey spheres) expressed from the transposase plasmid catalyzes the integration of the transposon into the host genome, providing an integrative non-viral gene transfer strategy. (B) Schematic representation of the four different plasmid constructs used in this study: the SB100X transposase plasmid pCMV(CAT)T7-SB100X for expression of the SB100X transposase and the three transposon plasmids containing mVWF, pT2-CAG-mVWF, pT2-HCRHPi-mVWF and pSA-HCRHPi-mVWF. The SB transposons pT2-CAG-mVWF and pT2-HCRHPi-mVWF have, respectively, a ubiquitous and a liver-specific promoter. The pSA-HCRHPi-mVWF plasmid is characterized by sandwich-designed SB transposon units in an inverted orientation. Due to mutations in the inner inverted repeats, the individual SB units cannot transpose. This sandwich-designed transposon is known to more efficiently transpose larger transgenes.
disorder. Type 3 is the most severe form of VWD, characterized by a complete deficiency of VWF, resulting in mucosal hemorrhages and serious bleeding after surgery or dental extractions. Severe VWD patients concomitantly have low levels of FVIII and may also suffer from hemophilia-like bleeding problems [13, 14] . The direct physical threat of acute, often life-threatening, bleedings, together with the general impact on health-related quality of life has been associated with anxiety and depression [15] [16] [17] [18] [19] . Current therapy for type 3 VWD patients is based on administration of exogenous VWF/FVIII products [20, 21] . Although these on-demand treatments are effective in most cases of acute hemorrhage, they only result in short-term correction of the bleeding phenotype due to the short half-life of VWF (6-24 h, depending on the origin). Gene therapy offers the potential for long-term correction of this monogenic blood protein disorder. In recent years, several gene therapy approaches for severe VWD have been reported, but these strategies were generally hampered by the large size of the VWF cDNA (8.4 kb) and the transient expression of VWF [22] [23] [24] [25] [26] . The goal of this study was to use the SB100X system to obtain stable gene transfer and long-term VWF expression in a mouse model of severe VWD.
Materials and methods

Mice
VWF-deficient (Vwf
À/À
) [27] and wild type (WT) C57BL/ 6J mice (The Jackson Laboratory, Bar Harbor, ME, USA) were used in this study. All animal experiments were approved by the Institutional Animal Care and Use Committee of the KU Leuven (Belgium).
The Sleeping Beauty transposon system
The SB100X transposon technology is a two-component system consisting of a transposon plasmid containing the gene of interest and a plasmid encoding the hyperactive SB100X transposase (pCMV(CAT)T7-SB100X) (Fig. 1B ) [2] . For this study, three different transposon plasmids containing murine VWF (mVWF) were constructed. First, pT2-CAG-mVWF (Fig. 1B) is a transposon containing mVWF under control of the CAG promoter consisting of a cytomegalovirus (CMV) early enhancer, a chicken b actin promoter and a rabbit b-globin splice acceptor site. This transposon plasmid was constructed by isolation of the mVWF cDNA from pcDNA6.1-CMV-mVWF [25] and ligation into pT2-CAG-AMAXA-GFP [2] after removal of the Green Fluorescent Protein (GFP). Second, pT2-HCRHPi-mVWF (Fig. 1B) is a transposon containing mVWF under control of the previously described HCRHPi liver-specific promoter [25] . This transposon plasmid was constructed by retrieving the HCRHPi promoter from pAAV-HCRHPi-MCS [25] and ligation into pT2-CAG-mVWF after removal of the CAG promoter. Third, pSA-HCRHPi-mVWF (Fig. 1B) is a sandwich-designed transposon also containing mVWF under control of the liver-specific HCRHPi promoter. For this third plasmid, the HCRHPi-mVWF fragment was isolated from pBS-HCRHPi-mVWF [25] Collection of blood samples and analysis of plasma VWF antigen levels, VWF multimers and FVIII activities were performed as previously described [25, 28] .
Immunohistochemistry
The presence of VWF in liver tissue after hydrodynamic gene transfer was assessed via indirect fluorescent immunohistochemistry. Isolated liver tissue was snap frozen in liquid nitrogen. Nine-micrometer cryosections were obtained using a Leica CM 1950 cryostat (Leica Biosystems, Nussloch, Germany) and stored at À20°C for further analysis. After fixation with 4% paraformaldehyde (Merck, Darmstadt, Germany) and washing with PBS, cryosections were incubated with blocking solution containing 3% bovine serum albumin (Albumin Fraktion V; Carl Roth, Karlsruhe, Germany), 1% normal swine serum (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) and 0.2% Triton TM X-100 (SigmaAldrich, St. Louis, MO, USA) for 30 min at room temperature (RT). Sections were incubated with a polyclonal rabbit anti-human (h)VWF antibody (1 : 200, Dako, Glostrup, Denmark) for 1 h at 37°C. After washing, fluorescein isothiocyanate (FITC)-labeled swine antirabbit-Ig antibody (1 : 40, Dako, 1 h at RT) was used for detection. The slides were mounted using Prolong Ò Gold antifade with 4 0 ,6-diamidino-2-phenylindole (DAPI) (Life Technologies TM , Carlsbad, CA, USA) and visualized using a Zeiss LSM710 Laser Scanning Confocal Microscope (Carl Zeiss AG, Oberkochen, Germany).
Tail clip bleeding time assay and saphenous vein bleeding model
Tail clip bleeding times were assessed as previously described [25] . To quantify the blood loss, the number of red blood cells collected during the bleeding was counted using a Hemavet 950FS Veterinary Multi-species Hematology system (Drew Scientific, Miami Lakes, FL, USA). Each mouse was only used once for bleeding time measurement.
Bleeding times in the saphenous vein bleeding model were determined as previously described [29] with modifications. Briefly, mice were anesthetized and placed in a lying prone position on a heating pad. After hair removal and disinfection of the hind leg, the saphenous vein was exposed using a skin incision. To initiate bleeding, the saphenous vein was punctured with a sterile 23G needle. Blood drops were absorbed on cellulose swabs by careful dipping every 10 s. If bleeding did not stop within 600 s, the experiment was ended. The bleeding time was defined as time until complete cessation of bleeding from the punctured site as observed through a microscope (Zeiss Stemi 2000-C Stereo Microscope; Carl Zeiss AG). Per experiment, three consecutive punctures were made more distally on the same saphenous vein and the average bleeding time was used as bleeding parameter.
CCl 4 -induced liver regeneration
Carbon tetrachloride (CCl 4 )-induced liver injury and regeneration in mice was used to confirm stable genomic integration and was performed as previously described [30] .
High throughput integration site analysis
The integration pattern of the SB-mediated delivery of the mVWF transgene was assessed via high-throughput integration site analysis (linear amplification-mediated [LAM] PCR) [31] . Briefly, to generate SB integration libraries, 1-5 lg of the purified genomic DNA (DNeasy (Table S1 ). Linear amplification using biotinylated LAM SB-50-bio primer (Table S1 ) was performed in two subsequent PCRs (50 cycles). The resulting ssDNA was collected using M-280 Streptavidine Dynabeads (Invitrogen, Carlsbad, CA, USA) and eluted in 10 lL water. The genomic sequences next to the SB left arm were amplified and barcoded in three subsequent PCRs (SB-20hmr-Bio and Linker primers; SB_PE_new_bc1 (or bc2, or bc3) and Nested primers; PE_nest_ind1 and Illumina 1 primers; Table S1 ). Following purification (QIA-GEN Ò MinElute Gel Extraction Kit), the A-tailed products were ligated in pGEMT vector. After quality control the resulting libraries were pooled and sequenced on a single flow cell lane on an Illumina HiSeq Genome Analyzer platform with a rapid 1X100 bp single end run setting via the Illumina Genome Analyzer platform.
To analyze the sequencing data, sample-specific barcoded sequencing reads were demultiplexed using CASAVA, an Illumina software package. The quality of sequencing runs of the resulting FASTQ files was evaluated using FastQC (http://www.bioinformatics.babraham.ac. uk/projects/fastqc). Reads starting with the barcode 5 0 -GTATGTAAACTTCCGACTTCAACTG-3 0 that follows the TA dinucleotide, which is characteristic of SB integration, were aligned against the latest version of the mouse reference genome (GRCm38/mm10 (Dec, 2011)), using Bowtie2 [32] . Only reads that mapped exactly to a unique position in the reference genome were kept for further analysis. To analyze the distribution of integrations, annotations of exons and coding sequences (CDS) of the corresponding reference genome were downloaded and the percentage of integration sites overlapping with the given genomic coordinates was analyzed using BEDTools [33] . Chromosomal distributions of integration sites were visualized on an ideogram using the NCBI Genome Decoration Page (http://www.ncbi.nlm.nih.gov/genome/tools/gdp/).
Statistical analysis
All data are expressed as mean AE standard error of the mean (SEM). Statistical analyses were performed using Prism 5.04 (GraphPad Software, La Jolla, CA, USA). Normal distribution of the datasets was tested using the D'-tino and Pearson omnibus normality test. A KruskalWallis test with Dunn's multiple comparison post-test was used to compare all groups of tail clip bleeding and saphenous vein bleeding experiments with the respective Vwf À/À control groups. Correlations were determined using the Spearman correlation test. A level of significance of 0.05 was considered in all statistical analyses.
Results
Construction of Sleeping Beauty transposons for VWF gene transfer
Previously, we reported that hydrodynamic liver-directed delivery of mVWF expression plasmids in VWF-deficient (Vwf À/À ) mice supported supra-physiological expression levels of transgene mVWF [25, 34] . However, expression was rapidly lost due to the non-integrative nature of the vectors. In the current study, we used the SB100X transposon technology to deliver and express mVWF cDNA (Fig. 1A) , aiming at long-term expression. Three different VWF transposon plasmids were constructed (Fig. 1B) : pT2-CAG-mVWF (containing mVWF under control of a CAG promoter consisting of a CMV early enhance, a chicken b actin promoter and a rabbit b-globin splice acceptor site), pT2-HCRHPi-mVWF (containing mVWF under control of the liver-specific HCRHPi promoter [25] ) and pSA-HCRHPi-mVWF (a sandwich-designed transposon containing mVWF under control of the liverspecific promoter). We previously showed that the liverspecific HCRHPi promoter (containing an apolipoprotein E hepatic control locus region linked to a human a1-antitrypsin promoter and a truncated 1.4 kb human factor IX intron A) is potent for efficient liver-directed transgene VWF expression [25] .
Stable and long-term expression of transgene VWF via Sleeping Beauty transposons
The constructed SB transposons were tested for supporting long-term VWF expression. The pT2-HCRHPimVWF transposon was hydrodynamically injected into Vwf À/À mice with (n = 28) or without (n = 5) the helper SB100X transposase plasmid. At regular time-points after gene transfer, blood samples were collected to determine plasma mVWF antigen levels via ELISA ( Fig. 2A) . Transgene mVWF levels peaked 3 days after gene delivery (187 AE 33%), before mVWF expression stabilized for more than half a year, still reaching 22 AE 4% 28 weeks after gene transfer (end of the study). As expected, control Vwf À/À mice injected with only the pT2-HCRHPimVWF transposon plasmid (no transposase) showed transient mVWF expression (peak levels of 195 AE 36% 3 days post-injection) that was completely lost after 10 weeks (Fig. 2A) . Expression levels using this liver-specific promoter-driven transposon, pT2-HCRHPi-mVWF, were significantly higher in comparison with the pT2-CAG-mVWF transposon plasmid, containing a less potent ubiquitous CAG promoter ( Figure S1 ). Nevertheless, using the pT2-CAG-mVWF transposon, lower levels of mVWF expression remained also stable for more than 1 year after injection (0.8 AE 0.3% 53 weeks post-injection, end of the study; Figure S1 ). In parallel, we also built a therapeutic gene delivery construct in the sandwich-designed version of SB, which was reported to have a superior ability to transpose larger transgenes [8, 9] , a feature particularly relevant for the VWF cDNA. Combination of the liver-specific VWF transgene cassette and the sandwich-designed transposon resulted in the pSA-HCRHPi-mVWF transposon. Hydrodynamic injection of this sandwich VWF transposon in Vwf À/À mice (n = 13), together with the SB100X transposase plasmid, resulted in even higher long-term expression of transgene mVWF compared with pT2-HCRHPi-mVWF ( Fig. 2A) . High peak levels of transgene mVWF were detected 3 days post-injection (2492 AE 1174%), after which the levels gradually declined. Remarkably, 6 weeks post-injection, mVWF levels stabilized around 300% of normal values and these supraphysiological levels were maintained up to 1.5 years post-injection (260 AE 95%, end of the study; Fig. 2A ). These results demonstrate the superior capacity of the sandwich transposon to support long-term expression of the large VWF transgene. To further confirm sustained synthesis of transgene mVWF in hepatocytes, livers of the treated mice were isolated and stained for mVWF (Fig. 2B) . In line with the high plasma mVWF levels, VWF-positive cells were abundantly present in stained liver sections up to 78 weeks after gene transfer (end of the experiment).
Surprisingly, injection of the pSA-HCRHPi-mVWF transposon alone (without transposase, n = 8) also resulted in prolonged expression of supra-physiological levels of mVWF ( Fig. 2A) . Although transgene mVWF levels continuously decreased over the period of 1.5 years after injection (48 AE 38% 78 weeks post-injection), they only declined below physiological level (100%) after 60 weeks following administration. This reflects a prolonged transgene expression supported by the sandwich structure of the transposon.
In conclusion, use of the liver-specific promoter in combination with the sandwich transposon design and the SB100X transposase forms a robust platform for longterm, supra-physiological transgene mVWF expression in Vwf À/À mice.
Integration of the VWF transposons into the liver genome
To investigate the fate of the large mVWF cDNA in the liver genome, low doses of carbon tetrachloride (CCl 4 ) were used in a subset of mice to induce liver injury and regeneration (Fig. 3) . Regenerated hepatocytes will only express the transgene after stable integration in the genome. After CCl 4 -induced liver regeneration, expression of transgene mVWF was rapidly lost in Vwf À/À mice treated with the pSA-HCRHPi-mVWF transposon without transposase. Consequently, prolonged expression from the pSA-HCRHPi-mVWF transposon without transposase is unlikely to originate from stable transgene integration. In mice treated with both transposon and transposase, however, mVWF expression remained stable upon CCl 4 -induced liver injury, indicating that the mVWF cDNA was integrated and could be passed on to newly generated liver cells. In order to study the integration profile of the sandwich-designed SB transposon vector system, a highthroughput integration site analysis was performed via linear amplification-mediated PCR (LAM-PCR), followed by deep sequencing (Fig. 4) . Liver samples of mice hydrodynamically injected with the pSA-HCRHPi-mVWF that were hydrodynamically injected with either the transposon plasmid pT2-HCRHPi-mVWF with (•, n = 28; two independent series of n = 14) or without (○, n = 5) the SB100X transposase plasmid or with the sandwich-designed VWF transposon plasmid pSA-HCRHPi-mVWF with (■, n = 13; two independent series of n = 5 and n = 8) or without (□, n = 8; two independent series of n = 5 and n = 3) the SB100X transposase plasmid. Results are expressed as percentage of VWF levels in normal murine plasma (NMP; 100%, dotted line) and presented as mean values AE standard error of the mean (SEM). The detection limit of the ELISA is represented by the dashed line (0.2%). (B) VWF-expressing liver cells remain abundantly present over time in Vwf À/À mice treated with the sandwich-designed VWF transposon. Vwf À/À mice were hydrodynamically injected with the sandwich-designed VWF transposon plasmid (pSA-HCRHPi-mVWF) and the SB100X transposase plasmid. At 12, 26, 53 and 78 weeks after hydrodynamic gene transfer, livers were isolated and stained for VWF using rabbit anti-VWF antibodies and anti-rabbit fluorescein isothiocyanate (FITC)-labeled secondary antibodies. Nuclei were visualized using 4 0 ,6-diamidino-2-phenylindole (DAPI). Liver cryosections from a mouse 12 weeks after gene transfer, stained without primary antibody (con), and a Vwf À/À mouse hydrodynamically injected with saline (Vwf À/À ) were used as negative controls. Pictures were taken using confocal microscopy, scale bars represent 50 lm.
plasmid with (SB) or without the SB100X transposase (controls) were both assessed (n = 3). The analysis identified on average 5626 AE 1703 and 113 AE 50 integration events in the SB and control mice, respectively (Fig. 4A) .
Only integration events with the threshold of at least five uniquely mapped reads per locus were considered. In the presence of the SB100X transposase, the integration events were 50-fold more frequent compared with insertion events in the control mice (Fig. 4A) , confirming that the transposase was capable of integrating the large transgene. Further analysis of the integration events revealed that most SB integrations were unique to their respective samples, reflecting the absence of analysis bias (Fig. 4B) . Analysis of the integration site distribution over the mouse genome revealed that the number of integration events in the three SB samples, but not in the controls, was proportional to the size of the chromosomes. These data suggest that, although the SB100X-mediated integration followed a close-to random pattern, the infrequent integration events in the absence of the transposase had no obvious pattern and can be considered as background (Fig. 4C , Wilcoxon ranked test W = 185, P = 0.698). Visualization of chromosomal distribution of the individual integration sites in SB samples on an ideogram shows a random distribution with no integration hotspots (Fig. 4D) . To evaluate biosafety, the identified integration sites were also annotated regarding their position in exons, UTRs, introns and intergenic regions of the reference genome (Fig. 4E) . Collectively, around 90% of all SB integrations occurred in intergenic and intronic regions, which are considered as 'safer harbors' for integrations than exons or UTRs. In conclusion, these experiments showed efficient transposase-mediated gene integration of the sandwich mVWF construct in Vwf À/À mice, allowing long-term and high-level expression of VWF in these animals. Similar to conventional SB transposon integration, the sandwich transposon construct also followed random integration. By contrast, the prolonged transgene VWF expression in the control mice did not occur via transposase-mediated transgene integration, suggesting that the sandwich construct was maintained episomally for a prolonged period of time.
FVIII activity after VWF gene transfer
To assess the functional effect of transgene VWF expression, we first monitored FVIII activity, which is markedly reduced in severe VWD. FVIII activity was measured in Vwf À/À mice that were hydrodynamically injected with both the sandwich transposon pSA-HCRHPi-mVWF and SB100X transposase constructs (n = 9, Figure S2 ). FVIII activity was restored to WT level 3 days post injection (131 AE 14%). From 20 weeks post injection onwards, FVIII activity stabilized around 40% of physiological levels, which was significantly higher than FVIII activity in untreated Vwf À/À mice (9 AE 1%, Figure S2 ).
Multimerization of liver-produced transgenic VWF
Because VWF activity is greatly dependent on the presence of high-molecular-weight (HMW) multimers, we studied the multimeric composition of transgeneexpressed mVWF after SB gene therapy (Fig. 5) . Despite the high level of transgene expression (> 100%), transgenic mVWF showed reduced relative amounts of HMW VWF multimers. Figure 5 shows VWF multimer profiles of five treated Vwf À/À mice. Whereas plasma mVWF from WT mice contains approximately 50% of HMW multimers, liver-expressed VWF consists of 22 AE 2% HMW multimers, 3 days post-injection. This fraction of HMW multimers declined further over time (3-7%) . The reduced amounts of HMW production can most probably be attributed to the fact that transgenic VWF is synthesized by hepatocytes instead of endothelial cells [22, 25] .
Correction of bleeding phenotype
Finally, the bleeding phenotype of the Vwf À/À mice treated via SB VWF transposon-mediated gene therapy was analyzed using the tail clip and saphenous vein bleeding models. In the tail clip bleeding assay, WT mice stopped bleeding within the first minutes after injury, whereas Vwf À/À mice bled for longer than 10 min, after which the experiment was stopped. Notably, at early time-points following gene transfer with the sandwich transposon system (pSA-HCRHPi-mVWF and transposase), tail clip bleeding times were corrected in the majority of mice. At later time-points, however, although some mice were still corrected, the majority of treated mice bled for longer than 10 min (Fig. 6A) . Because bleeding time does not differentiate between high and low blood loss, the volume of blood loss was measured. Similar to the bleeding time, blood loss was significantly reduced early after gene transfer compared with Vwf À/À mice. However, at later time-points, blood loss was reduced in some but not all treated animals (Fig. 6B) . In addition, we also used the saphenous vein bleeding model in which a less severe injury was inflicted. Bleeding times were significantly higher in Vwf À/À mice compared with WT animals.
Again, although some treated mice showed bleeding times lower than those in Vwf À/À mice, the majority did not show full correction of the bleeding phenotype (Fig. 6C) . A small but significant negative correlation was found between the amount of HMW VWF multimers and tail clip bleeding parameters ( Figure S3 ). Comparable tail bleeding results were obtained in mice treated with the less potent pT2-HCRHPi-mVWF transposon in combination with SB100X ( Figure S4 ).
Discussion
This study describes a novel SB100X transposon-based gene therapy platform for efficient integration of the large VWF transgene into the host genome. This non-viral gene transfer strategy supported long-term (> 1.5 years) and high (supraphysiological) expression of the large VWF transgene in a Vwf À/À mouse model after hydrodynamic gene transfer.
With our approach, we developed and assessed SB transposons by combining several elements for optimal VWF expression: (i) the hyperactive SB100X transposase that displays a~100-fold hyperactivity when compared with the originally resurrected transposase [2] , (ii) a potent liver-specific HCRHPi promoter [25] and (iii) a sandwich-designed transposon that is known to have superior ability to transpose larger transgenes [8, 9] . The combination of these three components allowed sustained expression of supra-physiological levels of VWF, in contrast to previous reports on gene therapy for VWD [23, 25, 35, 36] . To the best of our knowledge, this study is the first preclinical report on stable in vivo VWF gene transfer supporting expression of supraphysiological levels of VWF. The integrative nature of the SB system allows longterm expression of transgene VWF. We here demonstrated efficient integration of the VWF coding sequence into the host genome. Previous attempts, using lentiviral vectors, also achieved stable VWF gene transfer but were either performed in vitro in canine VWD type 3 blood outgrowth endothelial cells [22] or in vivo in newborn Vwf À/À mice where only low levels of VWF expression were obtained [24] . Besides efficient gene expression, an important biosafety issue when using integrating vectors is potential genotoxicity. Importantly, similarly to previous studies, our high-throughput integration site analysis revealed a close-to-random integration profile for SB-mediated integration. Although this integration pattern is safer in comparison to HIV lentiviruses, which show a bias towards integration into active transcription units [37] , targeted transposition into a safe-harbor chromosomal site would be ideal. Towards this end, SB fusion proteins with either zinc-finger DNA-binding domains or the adeno-associated virus Rep protein for site-specific DNA binding are currently being explored [38, 39] . Intriguingly, the long-term episomal maintenance of the sandwich transposon, observed in this study, could offer an alternative to integrating strategies for gene therapy and warrants further exploration. One important aspect of efficient VWF function is the formation of HMW multimers, as these are the most active VWF molecules in hemostasis. Previous studies using non-integrating plasmids targeting the liver of VWF-deficient mice resulted in transient expression of transgene VWF with a suboptimal multimerization pattern. Nonetheless, this liver-derived VWF was able to form platelet plugs at sites of vascular injury and to correct bleeding symptoms in Vwf À/À mice early after gene transfer [25, [34] [35] [36] 40 ]. In the current study, we observed a similar hemostatic capacity in the early phase after gene transfer, but unexpectedly not in a later phase. At later time-points, partial bleeding correction was observed in some individual mice, whereas the majority of treated mice did not show clear correction of the bleeding phenotype. The lack of full phenotypic correction can most likely be explained by the low amounts of HMW VWF multimers at these later time-points. The reason why efficient multimerization is gradually lost in hepatocytes is not clear but is likely to be due to differences in cellular machinery (e.g. Weibel-Palade bodies). Not only hepatocytes, but also other cell types (such as COS-7 [CV-1 in origin with SV40 genes] and CHO [chinese hamster ovary] cells), are known to synthesize transgene VWF with an altered multimer profile, whereas transgene-expressed VWF produced by type 3 VWD endothelial cells contains the full multimeric spectrum (including ultra-large VWF molecules) [22] . The lack of VWF in platelets after hydrodynamic injection is not likely to affect bleeding as plasma VWF has been shown to be sufficient for normal hemostasis in mice [28, 41] . Although hydrodynamic-based gene delivery in large animals shows promising applications, its clinical translation is currently limited [42] . Notably in vivo delivery of the SB transposon system using high-capacity adenoviral vectors (adeno-transposon hybrid) has been shown to result in persistent phenotypic correction of hemophilia dogs following a single intravenous administration [30] . Furthermore, this adenoviral/transposon hybrid technology was successfully used to target hematopoetic progenitor cells [43] . Future studies are needed to investigate whether such a clinically relevant hybrid system could support long-term SB100X-mediated VWF expression, preferably targeted to endothelial cells. Previous studies reported endothelial cell selective adenoviral vectors, either genetically engineered to expose endothelial cell binding peptides or derived from a rare serotype that demonstrated higher transduction of endothelial cells [44, 45] . Careful vector dosing should be investigated to avoid the potential thrombotic risk that could be associated with supra-physiological plasma levels of VWF with normal multimerization.
In conclusion, we achieved an important goal of developing a robust SB vector platform for efficient and stable VWF gene transfer. The next obvious step of VWD gene therapy would be to adapt this technology for delivery to an optimal cell type that is not only capable of stably producing the transgene at high expression levels, but also exhibits the full physiological capacity of multimer formation of transgenic VWF. Endothelial cells would be the most logical choice. Table S1 . Oligos used in the high-throughput integration site analysis. Fig. S1 . Sleeping Beauty (SB) transposon containing murine von Willebrand factor (mVWF) under control of the ubiquitous CAG promoter allows stable, long-term expression of mVWF in VWF-deficient mice, albeit at low levels. Fig. S2 . Sandwich-designed von Willebrand factor (VWF) transposon allows long-term restoration of FVIII activity at intermediate levels. Fig. S3 . Correlations of bleeding parameters with transgene murine von Willebrand factor (mVWF) levels and high-molecular-weight VWF multimers. Fig. S4 . Bleeding phenotype in mice treated with Sleeping Beauty (SB)-mediated von Willebrand factor (VWF) gene therapy.
